Inhibitors of Raf kinase and MEK signaling

Nithya Ramnath, Alex Adjei

Research output: Contribution to journalReview article

17 Scopus citations

Abstract

The RAS/RAF/MEK/ERK signaling pathway plays a central role in the regulation of many cellular processes including proliferation, survival, differentiation, apoptosis, motility and metabolism. This pathway is activated by a diverse group of extracellular signals including integrins, growth factor receptors [i.e. epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR)], or cytokines. While RAS, RAF and MEK activity appear restricted to only one class of substrates, ERK activates more than 70 substrates including nuclear transcription factors. Agents targeting the RAS/RAF/MEK/ERK pathway may therefore inhibit oncogenic signaling in tumor cells. However, most pharmacological agents directed against these targets have not been successful in the clinic. The only small molecule in this class to be approved for cancer therapy is sorafenib, which is not a pure RAF kinase inhibitor. To be successful, one may have to approach this pathway from a multi-pronged approach and also tailor therapy according to which component might be the one playing a pivotal role in a particular system. Relatively selective raf kinase inhibitors are entering clinical trials, and one MEK inhibitor, AZD6244 is in phase II clinical trials.

Original languageEnglish (US)
Pages (from-to)111-118
Number of pages8
JournalUpdate on Cancer Therapeutics
Volume2
Issue number3
DOIs
StatePublished - Sep 1 2007

Keywords

  • ERK
  • Inhibitors
  • MEK
  • RAF
  • RAS
  • Signal
  • Target
  • Transduction

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Inhibitors of Raf kinase and MEK signaling'. Together they form a unique fingerprint.

  • Cite this